TrialThe Lancet. Oncology2015

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Mohammed Z H Farooqui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.